Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Different levels of control prevent interferon-γ-inducible HLA-class II expression in human neuroblastoma cells

Abstract

The HLA class II expression is controlled by the transcriptional activator CIITA. The transcription of CIITA is controlled by different promoters, among which promoter-IV is inducible by IFN-γ. We analysed the regulation of HLA class II molecules by IFN-γ in a large series of human neuroblastoma cell lines. No induction of surface or intracellular HLA class II molecules and of specific mRNA was observed, in all neuroblastomas, with the exception of a nonprototypic cell line, ACN. In a large subset of neuroblastomas IFN-γ induced expression of CIITA mRNA, derived from promoter-IV, which was not methylated. In contrast, in another subset of neuroblastomas, CIITA was not inducible by IFN-γ and CIITA promoter-IV was either completely or partially methylated. Interestingly, the use of DNA demethylating agents restored CIITA gene transcriptional activation by IFN-γ, but not HLA class II expression. The defect of HLA class II was not related to alterations in RFX or NF-Y transcription factors, as suggested by EMSA or RFX gene transfection experiments. In addition, the transfection of a functional CIITA cDNA failed to induce HLA class II expression in typical neuroblastoma cells. Confocal microscopy and Western blot analysis suggested a defective nuclear translocation and/or reduced protein synthesis in CIITA-transfected NB cells. Altogether, these data point to multiple mechanisms preventing HLA class II expression in the neuroblastoma, either involving CIITA promoter-IV silencing, or acting at the CIITA post-transcriptional level.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  • Accolla RS, Jotterand-Bellomo M, Scarpellino L, Maffei A, Carra G and Guardiola J . (1986). J. Exp. Med., 164, 369–374.

  • Accolla RS, Mazza S, Barbara Ade L, Maria AD and Tosi G . (2002). Eur. J. Immunol., 32, 2783–2791.

  • Antunes NL, Khakoo Y, Matthay KK, Seeger RC, Stram DO, Gerstner E, Abrey LE and Dalmau J . (2000). J. Pediatr. Hematol. Oncol., 22, 315–320.

  • Armstrong TD, Clements VK, Martin BK, Ting JPY and Ostrand-Rosenberg S . (1997). Proc. Natl. Acad. Sci. USA, 94, 6886–6891.

  • Barbieri G, Deffrennes V, Prod'homme T, Vedrenne J, Baton F, Cortes C, Fischer A, Bono MR, Lisowska-Grospierre B, Charron D and Alcaide-Loridan C . (2002). Int. Immunol., 14, 839–848.

  • Blanck G . (1999). Microbes Infect., 1, 913–918.

  • Blanck G, Lok M, Kok K, Downie E, Korn JH and Strominger JL . (1990). Hum. Immunol., 29, 150–156.

  • Brocker EB, Suter L and Sorg C . (1984). J. Invest. Dermatol., 82, 244–247.

  • Collins T, Korman AJ, Wake CT, Boss JM, Kappes DJ, Fiers W, Ault KA, Gimbrone Jr MA, Strominger JL and Pober JS . (1984). Proc. Natl. Acad. Sci. USA, 81, 4917–4921.

  • Cooper MJ, Hutchins GM, Mennie RJ and Israel MA . (1990). Cancer Res., 50, 3694–3700.

  • Corrias MV, Occhino M, Croce M, De Ambrosis A, Pistillo MP, Bocca P, Pistoia V and Ferrini S . (2001). Tissue Antigens, 57, 110–117.

  • Cressman DE, O'Connor WJ, Greer SF, Zhu XS and Ting JP . (2001). J. Immunol., 167, 3626–3634.

  • Dignam JD, Lebovitz RM and Roeder RG . (1983). Nucleic Acids Res., 11, 1475–1489.

  • Dorn A, Bollekens J, Staub A, Benoist C and Mathis D . (1987). Cell, 50, 863–872.

  • Durand B, Sperisen P, Emery P, Barras E, Zufferey M, Mach B and Reith W . (1997). EMBO J., 16, 1045–1055.

  • Fulda S and Debatin KM . (2002). Oncogene, 21, 2295–2308.

  • Garrido F and Algarra I . (2001). Adv. Cancer Res., 83, 117–158.

  • Germain RN . (1994). Cell, 76, 287–299.

  • Glimcher LH and Kara CJ . (1992). Annu. Rev. Immunol., 10, 13–49.

  • Goblin SJP, Peijnenburg A, Keijsers V and van den Elsen PJ . (1997). Immunity., 6, 601–611.

  • Guermonprez P, Valladeau J, Zitvogel L, Thery C and Amigorena S . (2002). Annu. Rev. Immunol, 20, 621–667.

  • Khan R, Zhang XY, Supakar PC, Ehrlich KC and Ehrlich M . (1988). J. Biol. Chem., 263, 14374–14483.

  • Hake SB, Masternak K, Kammerbauer C, Janzen C, Reith W and Steimle V . (2000). Mol. Cell. Biol., 20, 7716–7725.

  • Harton JA and Ting JPY . (2000). Mol. Cell. Biol., 20, 6185–6194.

  • Lampson LA . (1990). J. Immunol., 144, 512–520.

  • Li G, Harton JA, Zhu X and Ting JP . (2001). Mol. Cell. Biol., 21, 4626–4635.

  • Lennon AM, Ottone C, Rigaud G, Deaven LL, Longmire J, Fellous M, Bono R and Alcaide-Loridan C . (1997). Immunogenetics, 45, 266–273.

  • Mantovani R . (1999). Gene, 239, 15–27.

  • Martin BK, Frelinger JG and Ting JPY . (1999). J. Immunol., 162, 6663–6670.

  • Meazza R, Comes A, Orengo AM, Ferrini S and Accolla RS . (2003). Eur. J. Immunol., 33, 1183–1192.

  • Moreno CS, Beresford GW, Loius-Plence P, Morris AC and Boss JM . (1999). Immunity, 10, 143–151.

  • Moreno CS, Emery P, West JE, Durand B, Reith W, Mach B and Boss JM . (1995). J. Immunol., 155, 4313–4321.

  • Morris AC, Spangler WE and Boss JM . (2000). J. Immunol., 164, 4143–4149.

  • Muhlethaler-Mottet A, Di Berardino W, Otten LA and Mach B . (1998). Immunity, 8, 157–166.

  • Muhlethaler-Mottet A, Otten LA, Steimle V and Mach B . (1997). EMBO J., 16, 2851–2860.

  • Nagarajan UM, Louis-Plence P, DeSandro A, Nilsen R, Bushey A and Boss JM . (1999). Immunity, 10, 153–162.

  • Naves R, Lennon AM, Barbieri G, Reyes L, Puga G, Salas L, Deffrennes V, Rosemblatt M, Fellous M, Charron D, Alcaide-Loridan C and Bono MR . (2002). Int. Immunol., 14, 481–491.

  • Nekrep N, Jabrane-Ferrat N and Peterlin BM . (2000). Mol. Cell. Biol., 20, 4455–4461.

  • Piskurich JF, Linhoff MW, Wang Y and Ting JP . (1999). Mol. Cell. Biol., 19, 431–440.

  • Redwine JM, Buchmeier MJ and Evans CF . (2001). Am. J. Pathol., 159, 1219–1224.

  • Reith W and Mach B . (2001). Annu. Rev. Immunol., 19, 331–373.

  • Reith W, Barras E, Satola S, Kobr M, Reinhart D, Sanchez CH and Mach B . (1989). Proc. Natl. Acad. Sci. USA, 86, 4200–4204.

  • Reith W, Satola S, Herrero Sanchez C, Amaldi I, Lisowska-Grospierre B, Griscelli C, Hadam MR and Mach B . (1988). Cell, 53, 897–906.

  • Reith W, Siegrist CA, Durand B, Barras E and Mach B . (1994). Proc. Natl. Acad. Sci. USA, 91, 554–558.

  • Rodriguez AM, Mallet W, Lenfant F, Arnaud J, Girr M, Urlinger S, Bensussan A and Le Bouteilleur P . (1997). Eur. J. Immunol., 27, 45–54.

  • Sartoris S, Valle MT, De Lerma Barbaro A, Tosi G, Cestari T, D'Agostino A, Megiovanni AM, Manca F and Accolla RS . (1998). J. Immunol., 161, 814–820.

  • Sheen-Chen SM, Chou FF, Eng HL and Chen WJ . (1994). Surgery, 116, 510–515.

  • Spilianakis C, Papamatheakis J and Kretsovali A . (2000). Mol. Cell. Biol., 20, 8489–8498.

  • Steimle V, Durand B, Barras E, Zufferey M, Hadam MR, Mach B and Reith W . (1995). Genes Dev., 9, 1021–1032.

  • Steimle V, Otten LA, Zufferey M and Mach B . (1993). Cell, 75, 135–146.

  • Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B and Mach B . (1994). Science, 265, 106–109.

  • Steinman RM . (1991). Annu. Rev. Immunol., 9, 271–296.

  • Temponi M, Kekish U, Hamby CV, Nielsen H, Marboe CC and Ferrone S . (1993). J. Immunol. Methods, 161, 239–256.

  • Ting JP-Y and Trowsdale J . (2002). Cell., 109, S21–S33.

  • Tosi G, Jabrane-Ferrat N and Peterlin BM . (2002). EMBO J., 21, 5467–5476.

  • Van den Elsen PJ, van der Stoep N, Vietor HE, Wilson L, van Zutphen M and Gobin SJP . (2000). Hum. Immunol., 61, 850–862.

  • Van der Stoep N, Biesta P, Quinten E and van den Elsen PJ . (2002). Int. J. Cancer, 97, 501–507.

Download references

Acknowledgements

This work has been supported by grants awarded by the AIRC (Italian Association for Cancer Research) and MIUR (Ministry of the University and Research). MO was supported by a fellowship from FIRC (Fondazione Italiana per la Ricerca sul Cancro) and MC from Italian Neuroblastoma Association.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Silvano Ferrini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Croce, M., De Ambrosis, A., Corrias, M. et al. Different levels of control prevent interferon-γ-inducible HLA-class II expression in human neuroblastoma cells. Oncogene 22, 7848–7857 (2003). https://doi.org/10.1038/sj.onc.1207054

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207054

Keywords

This article is cited by

Search

Quick links